ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Prognostic impact of tumour burden score on colorectal cancer liver metastasis survival following resection: a meta-analysis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purposeTumour burden score (TBS) shows promise for colorectal cancer liver metastasis (CRLM) prognostication, yet conflicting evidence has stalled its adoption. Our study evaluated the association between TBS and long-term outcomes after hepatectomy using a diagnostic meta-analysis workflow.
methodsWe searched seven databases through September 30, 2025, for retrospective cohorts supplying hazard ratios for TBS-based survival. Random-effects synthesis with Hartung-Knapp adjustment was used; heterogeneity was explored via leave-one-out analyses. Data integrity was verified with subgroup analysis, sensitivity analyses and trim-and-fill publication-bias assessment; GRADE rated certainty.
resultsThirteen cohorts (N = 5,100) were pooled. High TBS was linked to shorter overall survival (OS) (HR = 1.57; 95% CI: 1.36-1.81; k = 11); recurrence-free survival or disease-free survival in four cohorts yielded HR = 1.61 (95% CI: 1.32-1.96). One study with biologically implausible nonlinear hazards drove heterogeneity (I
conclusionTBS is an independent prognostic marker for post-hepatectomy CRLM survival. High TBS confers a 65% mortality hazard, warranting its inclusion in multidisciplinary risk-stratification algorithms.
Indexed as
Identifiers
42303946What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.